Fosamax (alendronate) is now approved for treating osteoporosis in men or women taking chronic glucocorticoids

August 1999

Fosamax (alendronate) is now approved for treating osteoporosis in men or women taking chronic glucocorticoids.

This new indication is for patients who take the equivalent of 7.5 mg/day or more of prednisone...AND have low bone mineral density.

These patients can lose up to 15% of their overall bone mass in their first year on steroids. Fractures occur in up to 50% of people on long-term steroids.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote